Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy.
Servizos
Servizos
Data de publicación
2011Título da revista
BREAST CANCER RESEARCH
Tipo de contido
Publicación de congreso
